©2022 Stanford Medicine
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Not Recruiting
Trial ID: NCT00846742
Purpose
This phase II trial is studying how well combination chemotherapy with or without radiation
therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in
chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride,
vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving
more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy
uses high-energy x-rays to kill cancer cells for those patients that still had residual
cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may
kill more cancer cells and allow doctors to save the part of the body where the cancer
started.
Official Title
Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Histologically confirmed, previously untreated Hodgkin lymphoma.
- Age: Participants must be 21 years of age or younger
- Stage must be classified as one of the following:
Ann Arbor stage IA or IIA with:
- Non-bulky mediastinal disease (< 33% mediastinal to thoracic ratio on CXR)
- < 3 nodal regions involved on the same side of the diaphragm
- No "E" lesion
- Female patients who are post-menarchal must have a negative pregnancy test. Patients
of reproductive potential must agree to use an effective contraceptive method.
- Signed informed consent
- If re-evaluation of a patient's disease shows intermediate risk features, the patient
will be removed from the HOD08.
Exclusion Criteria:
- Intermediate or High risk disease, defined as Stage IB, any III or IV or IA/IIA with
"E" lesion(s), 3 or more nodal sites involved, or bulky mediastinal adenopathy
Intervention(s):
radiation: Radiation Therapy
drug: Stanford V Chemotherapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Regina Dagher
650-725-4041